The kit, used on the Illumina MiSeqDx System, helps clinicians identify which patients are eligible for treatment with Amgen’s cancer drug Vectibix.
“The [kit] enables labs to implement an in-house solution for precision oncology and signifies that [next generation sequencing] has reached a milestone as a clinical diagnostic platform to aid therapeutic decision-making in oncology,” said Garret Hampton, PhD, Illumina’s executive vice president of clinical genomics.
Illumina will launch the kit in the third quarter of 2017.
More articles on supply chain:
New York City faces critical blood shortage
6 drug, device recalls in June
FDA approves Scibase’s melanoma detection device: 3 things to know
